William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.
William Kelly, MD
Advertisement
William Kelly, MD, is a medical oncologist specializing in neuro-oncology and thoracic oncology at the University of Texas Health San Antonio MD Anderson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the Mays Cancer Center.
Articles by William Kelly, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
5